stoxline Quote Chart Rank Option Currency Glossary
  
Oncternal Therapeutics, Inc. (ONCT)
0.5266  -0.167 (-24.12%)    12-02 16:00
Open: 0.7
High: 0.7
Volume: 644,135
  
Pre. Close: 0.694
Low: 0.5266
Market Cap: 2(M)
Technical analysis
2025-02-14 4:50:21 PM
Short term     
Mid term     
Targets 6-month :  0.61 1-year :  0.71
Resists First :  0.52 Second :  0.61
Pivot price 0.52
Supports First :  0.52 Second :  0.52
MAs MA(5) :  0.52 MA(20) :  0.52
MA(100) :  1.08 MA(250) :  5.12
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  0 D(3) :  0
RSI RSI(14): 25.1
52-week High :  10.61 Low :  0.52
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ONCT ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 82 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.53 - 0.53 0.53 - 0.53
Low: 0.52 - 0.52 0.52 - 0.53
Close: 0.52 - 0.53 0.53 - 0.53
Company Description

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

Headline News

Thu, 23 Jan 2025
ONCT stock price: Oncternal stock crashes by 60% after layoffs - Markets.com

Mon, 25 Nov 2024
Oncternal shares to be delisted from Nasdaq - Investing.com

Sun, 15 Sep 2024
Oncternal Therapeutics Axes B-Cell Lymphoma Trial for CAR-T Therapy ONCT-808 - CGTLive™

Fri, 13 Sep 2024
Oncternal to Lay Off 37% of Employees, Including CMO - BioSpace

Thu, 12 Sep 2024
Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives - Yahoo Finance

Thu, 12 Sep 2024
Oncternal folds all clinical trials after lackluster data drop, patient death - Fierce Biotech

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 3 (M)
Held by Insiders 2.71e+006 (%)
Held by Institutions 9.2 (%)
Shares Short 17 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 757.2 %
Return on Equity (ttm) -76.5 %
Qtrly Rev. Growth 2.16e+006 %
Gross Profit (p.s.) 482.13
Sales Per Share -86.81
EBITDA (p.s.) 0
Qtrly Earnings Growth -11.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -27 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 14210
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android